DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target?
Brain Sciences · 23.07.2024 · 14 (8) · 737
DOI: 10.3390/brainsci14080737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 23.07.2024. Verfasst von Hanieh Gholamalizadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Mashhad University of Medical Sciences, Mashhad 13131-99137, Iran. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autism spectrum disorder (ASD) is a group of heterogeneous neurodevelopmental disabilities with persistent impairments in cognition, communication, and social behavior. Although environmental factors play a role in ASD etiopathogenesis, a growing body of evidence indicates that ASD is highly inherited. In the last two decades, the dramatic rise in the prevalence of ASD has interested researchers to explore the etiologic role of epigenetic marking and incredibly abnormal DNA methylation. This review aimed to explain the current understanding of the association between changes in DNA methylation signatures and ASD in patients or animal models. We reviewed studies reporting alterations in DNA methylation at specific genes as well as epigenome-wide association studies (EWASs). Finally, we hypothesized that specific changes in DNA methylation patterns could be considered a potential biomarker for ASD diagnosis and prognosis and even a target for pharmacological intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Research Committee, Mashhad University of Medical Sciences, Mashhad 13131-99137, Iran.
- Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 91779-48564, Iran.
- Student Research Committee, North Khorasan University of Medical Sciences, Bojnurd 94149-75516, Iran.
- Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd 94149-75516, Iran.
- Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 91779-48564, Iran.
- Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad 91779-48564, Iran.
ORCID-Profile: Maedeh Amiri-Shahri, Vafa Baradaran Rahimi, Vahid Reza Askari
Zitieren
APA
Gholamalizadeh, H., Amiri-Shahri, M., Rasouli, F., Ansari, A., Baradaran Rahimi, V., & Reza Askari, V. (2024). DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target?. Brain Sciences, 14(8), 737. https://doi.org/10.3390/brainsci14080737
Vancouver
Gholamalizadeh H, Amiri-Shahri M, Rasouli F, Ansari A, Baradaran Rahimi V, Reza Askari V. DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target?. Brain Sciences. 2024;14(8):737. doi:10.3390/brainsci14080737
BibTeX
@article{Gholamalizadeh2024,
author = {Gholamalizadeh, Hanieh and Amiri-Shahri, Maedeh and Rasouli, Fatemeh and Ansari, Arina and Baradaran Rahimi, Vafa and Reza Askari, Vahid},
title = {DNA Methylation in Autism Spectrum Disorders: Biomarker or Pharmacological Target?},
journal = {Brain Sciences},
year = {2024},
volume = {14},
number = {8},
pages = {737},
doi = {10.3390/brainsci14080737}
}
EUVIMED